---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-029173"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2021-12-23T23:59:59+00:00"
generated_at: "2026-06-27T22:45:02.969949+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs announces new segment reporting structure effective Q3 FY2022

## Summary
- Four new segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, Calibration Solutions.
- Clinical Genomics segment consists of recently acquired Agena Bioscience business.
- Calibration Solutions combines former Instruments and Continuous Monitoring segments.
- Over 90% of future revenues expected from pharma, medical device, and healthcare verticals.
- Change reflects management's focus on higher-growth Life Sciences Tools applications.

## SEC filing metadata
- accession: 0001437749-21-029173
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2021-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774921029173/0001437749-21-029173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774921029173/mlab20211221_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-029173
- JSON: https://secwatch.observer/filing/0001437749-21-029173.json
- Plain text: https://secwatch.observer/filing/0001437749-21-029173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.